Join Aura Biosciences (#AURA) for a virtual urologic oncology investor event on Thurs. Oct 17 at 4:30pm ET featuring Max Kates, MD (Brady Urological Institute at Johns Hopkins), Joe Jacob, MD, MCR (SUNY Upstate), Neal Shore, MD, FACS (Carolina Urologic Research Center) and Gary Steinberg, MD, FACS (Rush University). The KOLs will discuss the early non-muscle invasive bladder cancer (NMIBC) data from Aura’s ongoing Phase 1 trial as well as the high unmet medical need and current treatment landscape in NMIBC. Register here: https://bit.ly/4dnqcgD
LifeSci Advisors, LLC’s Post
More Relevant Posts
-
MammaPrint can accurately identify which patients with HR+ early-stage breast cancer benefit from extending endocrine therapy
Agendia announced today that the NSABP B-42 study evaluating the MammaPrint assay in predicting the benefit of extended endocrine therapy in early-stage breast cancer patients was just published in the Journal of Clinical Oncology. The findings underscore MammaPrint's utility in accurately predicting which patients benefit from the addition of EET to their treatment regimens, establishing MammaPrint as the most comprehensive standalone genomic test for short and long-term treatment planning. Read the full publication here: https://lnkd.in/ghigEjM8
-
-
According to Yen-Shen Lu, MD, PhD, National Taiwan University Hospital, and coauthors, “This final analysis of the RIGHT Choice trial showed a clinically meaningful, statistically significant PFS benefit with first-line ribociclib plus [endocrine therapy] over combination [chemotherapy] in premenopausal women with clinically aggressive HR+/HER2– [advanced breast cancer] in which combination [chemotherapy] is typically is used to achieve a rapid tumor response." Learn more: https://lnkd.in/eUUQ6JjS
-
-
🌍 📰 The international phase III ENGOT study (InnovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin vs Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer) in which the GINECO has participated and which was presented last year at ESMO - European Society for Medical Oncology, has just been published in the New England Journal of Medecine. #Congratulations to all participating ENGOT groups and all investigators ! 👏 👉 https://lnkd.in/eh79XybU
-
-
This study compares the effects of neoadjuvant immune-oncology (IO) based regimens on patients with renal cell carcinoma (RCC) with and without tumor thrombus. Listen to Wadih Issa from UT Southwestern present the results of the study in this MEDtalk from ASCO GU 2024. #ASCOGU24 #KidneyCancer #Oncology
-
Medicinal Chemist | Targeted Protein Degradation & MedChem Passionate | All opinions are my own
📚💡❗ARV-471 Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
tandfonline.com
-
Certara is proud to showcase our scientific excellence at PAGE 2024. We are honored to be presenting the following abstracts dedicated to 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗶𝗻 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁. ▶️ Comparison of tumor dynamics models and tumor growth inhibition metrics in support of decisions in early Phase Ib/II clinical oncology studies https://lnkd.in/e7NtepQN ▶️ Operating characteristics of TGI metrics to support early Phase Ib decisions in unresectable hepatocellular carcinoma patients based on an historical Phase III study (IMbrave150) https://lnkd.in/eJgTftzq
-
-
Leading the way in collaborative compounds, drug discovery and targeted therapeutics - what a joy to share that the joint effort of Moderna & Carisma Therapeutics has yielded the first in a series of candidates. This nomination leverages mRNA-based in vivo CAR-M to develop a novel cell therapy targeting GPC3 in solid tumors - and which is known to be highly expressed in hepatocellular carcinoma. "HCC is the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the U.S." Let's bring forward some new options for patients! #HCC #LiverCancer #PatientPotential #mRNA #Macrophage #Monocyte #GPC3 #Glypican3 #collaboration #drugdiscovery #targetedtherapeutics #celltherapy #celliconvalley #immunotherapy #solidtumor #NasdaqCARM
We are excited to announce the nomination of the first Development Candidate under our collaboration with Moderna, Inc. The Development Candidate is an in vivo CAR-M targeting Glypican-3 and is designed to treat solid tumors, including hepatocellular carcinoma, the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the U.S. Read more in the press release here: https://lnkd.in/gpeaEx_v #Immunotherapy #CancerResearch #SolidTumors #LiverCancer #HCC
-
-
🚀 ASCO 2024 In Depth: Exciting Results from the DESTINY-Breast06 Trial Presented at ASCO 2024! Discover the latest findings from the DESTINY-Breast06 trial, as discussed by Prof Dr Giuseppe Curigliano, medical oncologist at the European Institute of Oncology and the University of Milan, and Dr Elisa Agostinetto, medical oncologist at the Institut Jules Bordet in Brussels, Belgium. The trial demonstrated that treatment with T-DXd significantly improved median PFS in HR-positive, HER2-low, and HER2-ultralow breast cancer patients compared to physician's choice chemotherapy. Watch the expert discussion video to learn more about this groundbreaking therapeutic option and its clinical applicability for patients with minimal HER2 expression. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #BreastCancer #Oncology #ClinicalTrials #CancerTreatment #HER2
-
Regenerative Medicine Business Development Manager @ Thermo Fisher | Cell and Gene Therapy
A new tumor-on-chip model has been developed that mimics the 3D microenvironment of solid tumors with vasculature-like perfusion. This innovative platform allows for CAR-T cell infusion, recruitment, and infiltration studies, along with dynamic cytokine release monitoring for over a week. By integrating primary breast cancer organoids, researchers can assess patient-specific CAR-T cell efficacy, paving the way for personalized treatments. https://lnkd.in/dQ25M-vw Discover how Thermo Fisher's cell culture products helped play a crucial role in developing this model, reducing inconsistencies and enhancing reliability. https://lnkd.in/dnSA95rw
-
-
⚡️ Advancing precision oncology in urothelial cancer: Pre-treatment metastatic biopsies capture real-time tumor biology, addressing heterogeneity missed in primary samples. This approach enhances prediction of response to therapies like enfortumab vedotin and FGFR inhibitors, guiding better treatment choices for patients with metastatic urothelial cancer. #BladderCancer https://buff.ly/3YK9Drj.
-
